ZHONGSHENGYAOYE(SZ:002317) Zheng Quan Zhi Xing·2025-06-24 18:41Core Viewpoint - The company has approved the use of raised funds to provide loans to its subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., for the implementation of a new drug research and development project, amounting to a maximum of RMB 110 million [1][2][10]. Summary of Relevant Sections Fundraising Overview - The company raised a net amount of RMB 590.20 million after deducting issuance costs of RMB 8.37 million, as approved by the China Securities Regulatory Commission [1][2]. - The funds were deposited into a designated account on June 15, 2023, and verified by an accounting firm [1]. Changes in Fund Usage - The company decided to reduce the budget for the "Anti-tumor Drug R&D Project" from RMB 169.20 million to RMB 43.26 million, reallocating the reduced amount of RMB 125.94 million to the "Drug R&D Center and Supporting Facilities Construction Project" [1][2]. - The remaining unused funds from the "Anti-tumor Drug R&D Project" and "Digital Platform Upgrade Project" totaling RMB 103.08 million will now be used for the new drug R&D project at the subsidiary [2][5]. Loan Details - The loan to the subsidiary will be provided in stages based on actual project needs, with a term of 5 years and an interest rate referencing the Loan Prime Rate (LPR) [1][2][10]. - The board of directors has authorized the chairman or designated agents to handle related matters and sign necessary documents [1][10]. Financial Status of the Subsidiary - As of March 31, 2025, the subsidiary had total assets of RMB 670.36 million and total liabilities of RMB 219.90 million, resulting in net assets of RMB 450.46 million [11]. - The subsidiary reported a total revenue of RMB 125.27 million for the first quarter of 2025, with a net loss of RMB 528.35 million for the same period [11]. Related Party Transactions - The loan constitutes a related party transaction, as the subsidiary is controlled by the company, and the terms are deemed fair and reasonable [8][9][10]. - The independent directors and supervisory board have approved the transaction, confirming it aligns with legal regulations and does not harm the interests of shareholders [14][15].